A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

NCT01690871 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Malignant PEComa (Perivascular Epithelioid Cell Tumors)

Interventions

DRUG: BEZ235

Sponsor

Novartis Pharmaceuticals